Brief: Xencor And Atreca Enter Strategic Collaboration To Discover, Develop And Commercialize Novel T Cell Engaging Bispecific Antibodies
08/07/2020 13:33
July 8 (Reuters) - Atreca Inc BCEL.O :
* XENCOR AND ATRECA ENTER STRATEGIC COLLABORATION TO
DISCOVER,
DEVELOP AND COMMERCIALIZE NOVEL T CELL ENGAGING BISPECIFIC
ANTIBODIES
* XENCOR INC - UNDER TERMS, CO, ATRECA WILL ENGAGE IN A
THREE-YEAR
DISCOVERY PROGRAM
* XENCOR - AGREEMENT ALLOWS EACH PARTNER TO PURSUE UPTO 2
PROGRAMS
INDEPENDENTLY, WITH MID- TO HIGH-SINGLE DIGIT PERCENT ROYALTY
PAYABLE ON NET SALES
* XENCOR - UNDER TERMS, ATRECA TO PROVIDE ANTIBODIES AGAINST
NOVEL
TUMOR TARGETS FROM WHICH XENCOR WILL ENGINEER XMAB BISPECIFIC
ANTIBODIES
Source text for Eikon: ID:nBw70K78Da
Further company coverage: BCEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atreca
See all newsBrief: Baker Bros Advisors Reports 19.99% Passive Stake In Atreca As Of Dec 31, 2023 - SEC Filing
Brief: Immunome To Acquire Antibody-Related Assets And Materials From Atreca
Brief: Atreca Says On Dec 19 Asset Sale And Other Transactions Contemplated By Agreement, Board Approved Liquidation And Dissolution Of Co
Brief: Atreca Q3 basic EPS USD -0.92
Brief: Atreca Announces Agreement To Terminate Lease And Departure Of CFO Herb Cross